(January 23, 2019) Researchers at Massachusetts General Hospital recently found a correlation between a class of drug used to treat hypertension and longer survival rates in ovarian cancer patients when used with paclitaxel, a drug used to treat ovarian cancer. The antihypertension drug used in a phase II clinical trial, losartan, aids the body in … Continued
Another reason you don’t want to miss OCRA’s Turn Up the Heat! Not only does the event feature fabulous tastings from DC’s female culinary stars—we are thrilled to announce that the amazing Chef Elle Simone, from PBS’ America’s Test Kitchen will be our host! Elle Simone Scott began dazzling the culinary world in 2003, and … Continued
(January 10, 2019) We’re pleased to announce OCRA’s newest research grants of $5.25 million to 23 top scientists at 14 top medical centers. In 2019, with our other ongoing grants and programs, OCRA is investing nearly $9 million in our fight against ovarian cancer. “OCRA invests in medical research to cure ovarian cancer. Scientists need … Continued
OCRA’s Turn Up the Heat is coming March 5th! Get your tickets now and treat yourself to our fabulous foodie fest, packed full of tantalizing treats and eats from the DC area’s most exciting female chefs, mixologists and restaurateurs, all for a good cause. We’re excited to announce that this year’s event will be hosted … Continued
Join our donors in supporting OCRA and your gift will have double the impact in the fight against ovarian cancer. Thanks to a generous year-end pledge from angel patrons and investment income to cover fundraising and administrative expenses, 100% of your gift will directly support OCRA’s research, education, patient support and advocacy programs. AND your … Continued
(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment. Study authors, including OCRA grantee Ursula Matulonis, MD, treated BRCA-1 deficient tumors with olaparib, a PARPi, and found that it began both a natural and medically induced … Continued
(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage epithelial ovarian, fallopian tube, and primary peritoneal cancers. Those included in the study … Continued
(December 7, 2018) A study published last month analyzed two clinical trials that sought to determine the best first step for advanced tubo-ovarian cancers, neoadjuvant chemotherapy or debulking surgery. The two studies, EORTC and CHORUS, had a total of 1,220 participants whose median age was 63 years. Both studies included stage IIIC and stage IV … Continued
Holiday Greeting Cards that Give Back Send your friends and family customizable cards from Picaboo Cards for Causes and show your support for finding an ovarian cancer cure. The front of the card is all yours to customize! Be as creative as you want, with one photo or several, and choose from many card layouts, … Continued
#GivingTuesday is November 27th, and we need you to help us make a big impact! Please join us in #GivingTeal, for the 22,000 American women diagnosed with ovarian cancer every year, and the 200,000 living with this disease. Here’s how you can help. Facebook Fundraisers On November 27th, Facebook will match donations up to $7 … Continued
(November 16, 2018) JAMA Internal Medicine recently published an eleven year study of over 72,000 women that found having a simple ovarian cyst does not increase one’s risk of ovarian cancer. The incidence of ovarian cancer in all age groups in the study was similar to women with normal ovaries. While simple cysts do not … Continued
(November 13, 2018) The International Journal of Cancer recently published a study that explored the use of statins, which reduces one’s lipids, and their effect on ovarian cancer risk. After comparing a group of 2,040 women diagnosed with epithelial ovarian cancer to a group of 2,100 women without the disease, it was found that statins … Continued
Get email updates about research news, action alerts, and ways to join the fight.
